The kisspeptin-1 receptor antagonist peptide-234 aggravates uremic cardiomyopathy in a rat model

Uremic cardiomyopathy is characterized by diastolic dysfunction, left ventricular hypertrophy (LVH), and fibrosis. Dysregulation of the kisspeptin receptor (KISS1R)-mediated pathways are associated with the development of fibrosis in cancerous diseases. Here, we investigated the effects of the KISS1...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Dinh Hoa
Kovács Zsuzsanna Z. A.
Márványkövi Fanni
Kis Merse
Kupecz Klaudia
Szűcs Gergő
Freiwan Marah
Lauber Gülsüm Yilmaz
Acar Eylem
Siska Andrea
Ibos Katalin Eszter
Bodnár Éva
Kriston András
Kovács Ferenc
Cserni Gábor
Dux László
Sárközy Márta
et al
Dokumentumtípus: Cikk
Megjelent: 2023
Sorozat:SCIENTIFIC REPORTS 13 No. 1
Tárgyszavak:
doi:10.1038/s41598-023-41037-0

mtmt:34123594
Online Access:http://publicatio.bibl.u-szeged.hu/28168
LEADER 02762nab a2200421 i 4500
001 publ28168
005 20230904094503.0
008 230904s2023 hu o 0|| Angol d
022 |a 2045-2322 
024 7 |a 10.1038/s41598-023-41037-0  |2 doi 
024 7 |a 34123594  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a Angol 
100 1 |a Dinh Hoa 
245 1 4 |a The kisspeptin-1 receptor antagonist peptide-234 aggravates uremic cardiomyopathy in a rat model  |h [elektronikus dokumentum] /  |c  Dinh Hoa 
260 |c 2023 
300 |a 16 
490 0 |a SCIENTIFIC REPORTS  |v 13 No. 1 
520 3 |a Uremic cardiomyopathy is characterized by diastolic dysfunction, left ventricular hypertrophy (LVH), and fibrosis. Dysregulation of the kisspeptin receptor (KISS1R)-mediated pathways are associated with the development of fibrosis in cancerous diseases. Here, we investigated the effects of the KISS1R antagonist peptide-234 (P234) on the development of uremic cardiomyopathy. Male Wistar rats (300–350 g) were randomized into four groups: (i) Sham, (ii) chronic kidney disease (CKD) induced by 5/6 nephrectomy, (iii) CKD treated with a lower dose of P234 ( ip. 13 µg/day), (iv) CKD treated with a higher dose of P234 ( ip. 26 µg/day). Treatments were administered daily from week 3 for 10 days. At week 13, the P234 administration did not influence the creatinine clearance and urinary protein excretion. However, the higher dose of P234 led to reduced anterior and posterior wall thicknesses, more severe interstitial fibrosis, and overexpression of genes associated with left ventricular remodeling ( Ctgf, Tgfb, Col3a1, Mmp9 ), stretch ( Nppa ), and apoptosis ( Bax, Bcl2, Casp7 ) compared to the CKD group. In contrast, no significant differences were found in the expressions of apoptosis-associated proteins between the groups. Our results suggest that the higher dose of P234 hastens the development and pathophysiology of uremic cardiomyopathy by activating the fibrotic TGF-β-mediated pathways. 
650 4 |a Általános orvostudomány 
700 0 1 |a Kovács Zsuzsanna Z. A.  |e aut 
700 0 1 |a Márványkövi Fanni  |e aut 
700 0 1 |a Kis Merse  |e aut 
700 0 1 |a Kupecz Klaudia  |e aut 
700 0 1 |a Szűcs Gergő  |e aut 
700 0 1 |a Freiwan Marah  |e aut 
700 0 1 |a Lauber Gülsüm Yilmaz  |e aut 
700 0 1 |a Acar Eylem  |e aut 
700 0 1 |a Siska Andrea  |e aut 
700 0 1 |a Ibos Katalin Eszter  |e aut 
700 0 1 |a Bodnár Éva  |e aut 
700 0 1 |a Kriston András  |e aut 
700 0 1 |a Kovács Ferenc  |e aut 
700 0 1 |a Cserni Gábor  |e aut 
700 0 1 |a Dux László  |e aut 
700 0 1 |a Sárközy Márta  |e aut 
700 0 1 |a et al.  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/28168/1/DinhH_SciRep_2023.pdf  |z Dokumentum-elérés